Ademi & O'Reilly, LLP is investigating the Board of Directors of NCI, Inc. (Nasdaq: NCIT) for possible breaches of fiduciary duty and other violations of Delaware law in connection with the sale of NCI to H.I.G. Capital, LLC. Click here to learn how to join the action: http://ademilaw.com/case/nci-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. Ademi & O'Reilly, LLP alleges NCI's long-term financial outlook is improving and yet NCI shareholders will receive only $20.00 per NCI common share. H.I.G. is well aware of NCI's improving financial metrics and is purchasing NCI at a substantial discount. The merger agreement unreasonably limits competing bids for NCI by (i) prohibiting solicitation of any further bids, and (ii) imposing a termination penalty should NCI receive and accept a superior bid. NCI insiders, their affiliates and other major shareholders own significant voting stock, and will receive millions of dollars as part of change of control arrangements, and therefore can unduly influence a sale of NCI. Our investigation centers on the conduct of NCI's Board of Directors, who have unanimously approved the transaction, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for NCI given its current financial condition and prospects. If you own common stock in NCI and wish to obtain additional information, please contact Guri Ademi either at email@example.com or toll-free: 866-264-3995, or http://ademilaw.com/case/nci-inc. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.